News on INS-1 Announcement that Insmed has discontinued its internal development of INS-1, one of its investigational drug candidates for type 2 diabetes and polycystic ovary syndrome (PCOS). http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=insm&script=410&layout=0&item_id=332626
